Hetriva 9mg Patch contains rivastigmine 9mg as its active ingredient, a reversible cholinesterase inhibitor indicated for the symptomatic treatment of mild to moderate dementia associated with Alzheimer's disease and Parkinson's disease. Rivastigmine enhances cholinergic function by inhibiting the breakdown of acetylcholine, thereby improving cognitive function and daily living activities in affected patients. The transdermal patch formulation allows for continuous, controlled delivery of rivastigmine over 24 hours, minimizing gastrointestinal side effects commonly associated with oral administration, such as nausea and vomiting. Hetriva 9mg Patch is applied once daily to clean, dry, and intact skin on the upper or lower back, chest, or upper arm, with sites rotated to reduce the risk of skin irritation. Dosage adjustment should be individualized based on patient tolerance and clinical response, with careful monitoring for adverse effects including dizziness, headache, and skin reactions at the application site. Use of Hetriva 9mg Patch is contraindicated in patients with known hypersensitivity to rivastigmine or any patch components. Caution is advised in patients with severe hepatic or renal impairment. This medication should be used under medical supervision, ensuring adherence to prescribed dosing and monitoring protocols to optimize therapeutic outcomes.